Nanobiotix NBTX 深 沪
已收盘 10-02 16:00:00 美东时间
25.75
-2.150
-7.71%
华盛通- 最 高27.425
- 今 开27.39
- 成交量 25.58万股
- 最 低 25.23
- 昨 收 27.90
- 总市值 131.12万
- 52周最高 57.14
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 14.78
- 委 比 98.68%
- 总股本 5.09万
- 历史最高 57.14
- 量 比 1.52
- 振 幅 7.87%
- 历史最低 1.75
- 每 手 1
- 风险率 8.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nanobiotix names new CFO
Nanobiotix (NBTX) said on Thursday that it appointed Arnd Christ as chief financial officer and member of the company’s executive board, effective October 1, 2026. Christ succeeds Bart Van Rhijn, who ...
10-02 04:37
Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.82) per share. This is a 583.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $6.533 million in sales this quarter. This is a 78.37 percent decrease over sales of $30.202 million the sa...
09-25 04:40
Voting Rights and Shares Capital of the Company
Nanobiotix, a late-stage clinical biotechnology company, has updated its voting rights and share capital as of August 31, 2026. The company, listed on Euronext Paris and Nasdaq, reported 50,941,528 shares outstanding and total voting rights of 54,701,246 (theoretical) and 54,679,128 (exercisable). Nanobiotix, founded in 2003 and headquartered in Paris, focuses on innovative nanotechnology platforms for oncology, bioavailability, and central nervo...
09-22 20:15
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64
Guggenheim analyst Paul Jeng assumes Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Target of $64.
09-15 21:17
Nanobiotix Says JNJ-1900 (NBTXR3) Shows 61% One-Year Local Progression-Free Survival And 70% One-Year Overall Survival In Phase 1 NSCLC Trial
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year locoregional control rate was 79%, one-year local progression-free survival (LP...
09-14 14:05
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Nanobiotix, a late-stage biotech company, announced that its management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York. The event will feature Laurent Lévy, CEO, and Bart Van Rhijn, Chief Financial and Business Officer. Nanobiotix, headquartered in Paris, specializes in physics-based therapies for cancer and other diseases, with over 30 patents across three na...
09-09 20:15
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 250 points on Wednesday. Shares of Sirius XM Holdings Inc (NASDAQ:SIRI) rose sharply during Wednesday’s session after Deutsche Bank upgraded the stock from Hold to Buy and raised its price target from $31 to $45. Sirius XM share...
09-02 22:26
Voting Rights and Shares Capital of the Company
Nanobiotix, a late-stage clinical biotechnology company, announced on August 25, 2026, that as of July 31, 2026, there were 50,833,462 shares outstanding, with total theoretical voting rights of 54,534,179 and exercisable voting rights of 54,512,061. The company, headquartered in Paris, France, is listed on Euronext Paris and Nasdaq, and has a subsidiary in Cambridge, Massachusetts. Nanobiotix, founded in 2003, owns over 30 patent families across...
08-25 20:15
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
